BONST
CELG

Bank of Nova Scotia Trust’s Celgene Corp CELG Stock Holding History

Bank of Nova Scotia Trust’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,500
Closed -$219K – 470
2017
Q3 		$219K Buy
+1,500
New +$204K 0.02% 131

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bank of Nova Scotia Trust's CELG Position: Q4 2017 in Review

Bank of Nova Scotia Trust sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 1,500 shares — an estimated $219K sold.

Bank of Nova Scotia Trust first reported a position in CELG in Q3 2017 and held it in 1 quarter. The position peaked at $219K in Q3 2017. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • Bank of Nova Scotia Trust reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
  • Bank of Nova Scotia Trust sold 1,500 Celgene Corp shares in Q4 2017, an estimated $219K.
  • Bank of Nova Scotia Trust first reported a position in Celgene Corp in Q3 2017 and held it in 1 quarter.
  • Bank of Nova Scotia Trust's Celgene Corp position peaked at $219K in Q3 2017.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Bank of Nova Scotia Trust's 13F filing for Q4 2017, filed 13 Feb 2018.